Biological warfare defense firm SIGA Technologies (Nasdaq: SIG) has filed a voluntary petition for relief under chapter 11 of the Bankruptcy Code in the US Bankruptcy Court for the Southern District of New York.
The filing allows SIGA to challenge an expected damages award to competitor USA-based biodefense company PharmAthene (NYSE MKT: PIP) of as much as $232 million without posting the bond (The Pharma Letter August 11). SIGA shares fell 21.5% to $1.13 in early trading today, while PharmAthene dropped 10.9% to $1.96.
Aims to preserve ability to satisfy smallpox drug delivery to government
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze